TY - JOUR
T1 - Negative regulation of estrogen receptor α transactivation functions by LIM domain only 4 protein
AU - Singh, Rajesh R.
AU - Barnes, Christopher J.
AU - Talukder, Amjad H.
AU - Fuqua, Suzanne A.W.
AU - Kumar, Rakesh
PY - 2005/11/15
Y1 - 2005/11/15
N2 - LIM domain only 4 (LMO4), a member of the LIM-only family of transcriptional coregulatory proteins, consists of two LIM protein-protein interaction domains that enable it to function as a linker protein in multiprotein complexes. Here, we have identified estrogen receptor α (ERα) and its corepressor, metastasis tumor antigen 1 (MTA1), as two novel binding partners of LMO4. Interestingly, LMO4 exhibited binding with both ERα and MTA1 and existed as a complex with ERα, MTA1, and histone deacetylases (HDAC), implying that LMO4 was a component of the MTA1 corepressor complex. Consistent with this notion, LMO4 overexpression repressed ERα transactivation functions in an HDAC-dependent manner. Accordingly, silencing of endogenous LMO4 expression resulted in a significant increased recruitment of ERα to target gene chromatin, stimulation of ERα transactivation activity, and enhanced expression of ERα-regulated genes. These findings suggested that LMO4 was an integral part of the molecular machinery involved in the negative regulation of ERα transactivation function in breast cells. Because LMO4 is up-regulated in human breast cancers, repression of ERα transactivation functions by LMO4 might contribute to the process of breast cancer progression by allowing the development of ERα-negative phenotypes, leading to increased aggressiveness of breast cancer cells.
AB - LIM domain only 4 (LMO4), a member of the LIM-only family of transcriptional coregulatory proteins, consists of two LIM protein-protein interaction domains that enable it to function as a linker protein in multiprotein complexes. Here, we have identified estrogen receptor α (ERα) and its corepressor, metastasis tumor antigen 1 (MTA1), as two novel binding partners of LMO4. Interestingly, LMO4 exhibited binding with both ERα and MTA1 and existed as a complex with ERα, MTA1, and histone deacetylases (HDAC), implying that LMO4 was a component of the MTA1 corepressor complex. Consistent with this notion, LMO4 overexpression repressed ERα transactivation functions in an HDAC-dependent manner. Accordingly, silencing of endogenous LMO4 expression resulted in a significant increased recruitment of ERα to target gene chromatin, stimulation of ERα transactivation activity, and enhanced expression of ERα-regulated genes. These findings suggested that LMO4 was an integral part of the molecular machinery involved in the negative regulation of ERα transactivation function in breast cells. Because LMO4 is up-regulated in human breast cancers, repression of ERα transactivation functions by LMO4 might contribute to the process of breast cancer progression by allowing the development of ERα-negative phenotypes, leading to increased aggressiveness of breast cancer cells.
UR - http://www.scopus.com/inward/record.url?scp=28544433968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28544433968&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-05-2268
DO - 10.1158/0008-5472.CAN-05-2268
M3 - Article
C2 - 16288053
AN - SCOPUS:28544433968
SN - 0008-5472
VL - 65
SP - 10594
EP - 10601
JO - Cancer Research
JF - Cancer Research
IS - 22
ER -